EP2029100A2 - Comprimé plat combiné ache-nmda - Google Patents
Comprimé plat combiné ache-nmdaInfo
- Publication number
- EP2029100A2 EP2029100A2 EP07725819A EP07725819A EP2029100A2 EP 2029100 A2 EP2029100 A2 EP 2029100A2 EP 07725819 A EP07725819 A EP 07725819A EP 07725819 A EP07725819 A EP 07725819A EP 2029100 A2 EP2029100 A2 EP 2029100A2
- Authority
- EP
- European Patent Office
- Prior art keywords
- preparation according
- dementia
- active
- active ingredients
- treatment
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 206010012289 Dementia Diseases 0.000 claims abstract description 31
- 239000013543 active substance Substances 0.000 claims abstract description 26
- 238000011282 treatment Methods 0.000 claims abstract description 21
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 14
- 229940124596 AChE inhibitor Drugs 0.000 claims abstract description 13
- 239000002664 nootropic agent Substances 0.000 claims abstract description 12
- 229920001477 hydrophilic polymer Polymers 0.000 claims abstract description 11
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 claims abstract description 10
- 239000005557 antagonist Substances 0.000 claims abstract description 8
- 238000000034 method Methods 0.000 claims abstract description 8
- 239000000544 cholinesterase inhibitor Substances 0.000 claims abstract description 3
- 239000004480 active ingredient Substances 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 42
- 238000002360 preparation method Methods 0.000 claims description 29
- 229940079593 drug Drugs 0.000 claims description 23
- 239000002552 dosage form Substances 0.000 claims description 22
- 239000000890 drug combination Substances 0.000 claims description 10
- 210000000214 mouth Anatomy 0.000 claims description 7
- 239000003703 n methyl dextro aspartic acid receptor blocking agent Substances 0.000 claims description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 6
- 229920001223 polyethylene glycol Polymers 0.000 claims description 6
- 229920000642 polymer Polymers 0.000 claims description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- BUGYDGFZZOZRHP-UHFFFAOYSA-N memantine Chemical group C1C(C2)CC3(C)CC1(C)CC2(N)C3 BUGYDGFZZOZRHP-UHFFFAOYSA-N 0.000 claims description 5
- 229960004640 memantine Drugs 0.000 claims description 5
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims description 4
- KBAFPSLPKGSANY-UHFFFAOYSA-N Naftidrofuryl Chemical compound C=1C=CC2=CC=CC=C2C=1CC(C(=O)OCCN(CC)CC)CC1CCCO1 KBAFPSLPKGSANY-UHFFFAOYSA-N 0.000 claims description 4
- 239000002202 Polyethylene glycol Substances 0.000 claims description 4
- 230000002378 acidificating effect Effects 0.000 claims description 4
- 235000010443 alginic acid Nutrition 0.000 claims description 4
- 229920000615 alginic acid Polymers 0.000 claims description 4
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- 239000006260 foam Substances 0.000 claims description 4
- ASUTZQLVASHGKV-JDFRZJQESA-N galanthamine Chemical compound O1C(=C23)C(OC)=CC=C2CN(C)CC[C@]23[C@@H]1C[C@@H](O)C=C2 ASUTZQLVASHGKV-JDFRZJQESA-N 0.000 claims description 4
- 229960001132 naftidrofuryl Drugs 0.000 claims description 4
- 230000001777 nootropic effect Effects 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- GMZVRMREEHBGGF-UHFFFAOYSA-N Piracetam Chemical compound NC(=O)CN1CCCC1=O GMZVRMREEHBGGF-UHFFFAOYSA-N 0.000 claims description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 229960004526 piracetam Drugs 0.000 claims description 3
- 229920006254 polymer film Polymers 0.000 claims description 3
- OMDQUFIYNPYJFM-XKDAHURESA-N (2r,3r,4s,5r,6s)-2-(hydroxymethyl)-6-[[(2r,3s,4r,5s,6r)-4,5,6-trihydroxy-3-[(2s,3s,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]methoxy]oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@H](O)[C@H](O)O1 OMDQUFIYNPYJFM-XKDAHURESA-N 0.000 claims description 2
- HPOIPOPJGBKXIR-UHFFFAOYSA-N 3,6-dimethoxy-10-methyl-galantham-1-ene Natural products O1C(C(=CC=2)OC)=C3C=2CN(C)CCC23C1CC(OC)C=C2 HPOIPOPJGBKXIR-UHFFFAOYSA-N 0.000 claims description 2
- UIAGMCDKSXEBJQ-IBGZPJMESA-N 3-o-(2-methoxyethyl) 5-o-propan-2-yl (4s)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylate Chemical compound COCCOC(=O)C1=C(C)NC(C)=C(C(=O)OC(C)C)[C@H]1C1=CC=CC([N+]([O-])=O)=C1 UIAGMCDKSXEBJQ-IBGZPJMESA-N 0.000 claims description 2
- SATHPVQTSSUFFW-UHFFFAOYSA-N 4-[6-[(3,5-dihydroxy-4-methoxyoxan-2-yl)oxymethyl]-3,5-dihydroxy-4-methoxyoxan-2-yl]oxy-2-(hydroxymethyl)-6-methyloxane-3,5-diol Chemical compound OC1C(OC)C(O)COC1OCC1C(O)C(OC)C(O)C(OC2C(C(CO)OC(C)C2O)O)O1 SATHPVQTSSUFFW-UHFFFAOYSA-N 0.000 claims description 2
- 229920001817 Agar Polymers 0.000 claims description 2
- 229920000936 Agarose Polymers 0.000 claims description 2
- 239000001904 Arabinogalactan Substances 0.000 claims description 2
- 229920000189 Arabinogalactan Polymers 0.000 claims description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims description 2
- 241000416162 Astragalus gummifer Species 0.000 claims description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 claims description 2
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 2
- 229920001661 Chitosan Polymers 0.000 claims description 2
- LPCKPBWOSNVCEL-UHFFFAOYSA-N Chlidanthine Natural products O1C(C(=CC=2)O)=C3C=2CN(C)CCC23C1CC(OC)C=C2 LPCKPBWOSNVCEL-UHFFFAOYSA-N 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 2
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 claims description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims description 2
- 229920002307 Dextran Polymers 0.000 claims description 2
- 229920000926 Galactomannan Polymers 0.000 claims description 2
- 108010010803 Gelatin Proteins 0.000 claims description 2
- 241000206672 Gelidium Species 0.000 claims description 2
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 2
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 claims description 2
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 claims description 2
- 229930195725 Mannitol Natural products 0.000 claims description 2
- 229920000881 Modified starch Polymers 0.000 claims description 2
- HOKKHZGPKSLGJE-UHFFFAOYSA-N N-methyl-D-aspartic acid Natural products CNC(C(O)=O)CC(O)=O HOKKHZGPKSLGJE-UHFFFAOYSA-N 0.000 claims description 2
- BYPFEZZEUUWMEJ-UHFFFAOYSA-N Pentoxifylline Chemical compound O=C1N(CCCCC(=O)C)C(=O)N(C)C2=C1N(C)C=N2 BYPFEZZEUUWMEJ-UHFFFAOYSA-N 0.000 claims description 2
- XSVMFMHYUFZWBK-NSHDSACASA-N Rivastigmine Chemical compound CCN(C)C(=O)OC1=CC=CC([C@H](C)N(C)C)=C1 XSVMFMHYUFZWBK-NSHDSACASA-N 0.000 claims description 2
- 229920002125 Sokalan® Polymers 0.000 claims description 2
- 229920002472 Starch Polymers 0.000 claims description 2
- 229920001615 Tragacanth Polymers 0.000 claims description 2
- 229930003427 Vitamin E Natural products 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 235000010419 agar Nutrition 0.000 claims description 2
- 239000000783 alginic acid Substances 0.000 claims description 2
- 229960001126 alginic acid Drugs 0.000 claims description 2
- 150000004781 alginic acids Chemical class 0.000 claims description 2
- 239000003963 antioxidant agent Substances 0.000 claims description 2
- 235000006708 antioxidants Nutrition 0.000 claims description 2
- 235000019312 arabinogalactan Nutrition 0.000 claims description 2
- 235000010385 ascorbyl palmitate Nutrition 0.000 claims description 2
- 239000000440 bentonite Substances 0.000 claims description 2
- 229910000278 bentonite Inorganic materials 0.000 claims description 2
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 2
- 239000007853 buffer solution Substances 0.000 claims description 2
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 2
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 2
- 235000010418 carrageenan Nutrition 0.000 claims description 2
- 229920001525 carrageenan Polymers 0.000 claims description 2
- 239000000679 carrageenan Substances 0.000 claims description 2
- 229940113118 carrageenan Drugs 0.000 claims description 2
- 229920002678 cellulose Polymers 0.000 claims description 2
- 239000001913 cellulose Substances 0.000 claims description 2
- 235000010980 cellulose Nutrition 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000007884 disintegrant Substances 0.000 claims description 2
- 239000000975 dye Substances 0.000 claims description 2
- 229910021485 fumed silica Inorganic materials 0.000 claims description 2
- 229960003980 galantamine Drugs 0.000 claims description 2
- BGLNUNCBNALFOZ-WMLDXEAASA-N galanthamine Natural products COc1ccc2CCCC[C@@]34C=CCC[C@@H]3Oc1c24 BGLNUNCBNALFOZ-WMLDXEAASA-N 0.000 claims description 2
- ASUTZQLVASHGKV-UHFFFAOYSA-N galanthamine hydrochloride Natural products O1C(=C23)C(OC)=CC=C2CN(C)CCC23C1CC(O)C=C2 ASUTZQLVASHGKV-UHFFFAOYSA-N 0.000 claims description 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims description 2
- 239000008273 gelatin Substances 0.000 claims description 2
- 229920000159 gelatin Polymers 0.000 claims description 2
- 235000019322 gelatine Nutrition 0.000 claims description 2
- 235000011852 gelatine desserts Nutrition 0.000 claims description 2
- 235000020686 ginkgo biloba extract Nutrition 0.000 claims description 2
- 235000011187 glycerol Nutrition 0.000 claims description 2
- 229920000578 graft copolymer Polymers 0.000 claims description 2
- 150000005419 hydroxybenzoic acid derivatives Chemical class 0.000 claims description 2
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 2
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 2
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 2
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 2
- IYVSXSLYJLAZAT-NOLJZWGESA-N lycoramine Natural products CN1CC[C@@]23CC[C@H](O)C[C@@H]2Oc4cccc(C1)c34 IYVSXSLYJLAZAT-NOLJZWGESA-N 0.000 claims description 2
- 239000000594 mannitol Substances 0.000 claims description 2
- 235000010355 mannitol Nutrition 0.000 claims description 2
- 230000000873 masking effect Effects 0.000 claims description 2
- 229920000609 methyl cellulose Polymers 0.000 claims description 2
- 239000001923 methylcellulose Substances 0.000 claims description 2
- 235000019426 modified starch Nutrition 0.000 claims description 2
- 229920001206 natural gum Polymers 0.000 claims description 2
- 229960000715 nimodipine Drugs 0.000 claims description 2
- 235000010987 pectin Nutrition 0.000 claims description 2
- 239000001814 pectin Substances 0.000 claims description 2
- 229920001277 pectin Polymers 0.000 claims description 2
- 239000000049 pigment Substances 0.000 claims description 2
- 229920000058 polyacrylate Polymers 0.000 claims description 2
- 229920000223 polyglycerol Polymers 0.000 claims description 2
- 229920001282 polysaccharide Polymers 0.000 claims description 2
- 239000005017 polysaccharide Substances 0.000 claims description 2
- 150000004804 polysaccharides Chemical class 0.000 claims description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 claims description 2
- 235000019422 polyvinyl alcohol Nutrition 0.000 claims description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 2
- 229960004136 rivastigmine Drugs 0.000 claims description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 2
- 239000000600 sorbitol Substances 0.000 claims description 2
- 235000010356 sorbitol Nutrition 0.000 claims description 2
- 235000019698 starch Nutrition 0.000 claims description 2
- 239000008107 starch Substances 0.000 claims description 2
- 229940042585 tocopherol acetate Drugs 0.000 claims description 2
- 235000010487 tragacanth Nutrition 0.000 claims description 2
- 239000000196 tragacanth Substances 0.000 claims description 2
- 229940116362 tragacanth Drugs 0.000 claims description 2
- 229940124549 vasodilator Drugs 0.000 claims description 2
- 239000003071 vasodilator agent Substances 0.000 claims description 2
- 235000019165 vitamin E Nutrition 0.000 claims description 2
- 229940046009 vitamin E Drugs 0.000 claims description 2
- 239000011709 vitamin E Substances 0.000 claims description 2
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 2
- QHZUABXEBRGBLP-LKWYKXIFSA-N (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-4-benzyl-9b-hydroxy-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,9R,10aR)-N-[(2R,4R,9aS,9bR)-9b-hydroxy-3,5-dioxo-2,4-di(propan-2-yl)-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide (6aR,10aR)-N-[(2S,4S,9bS)-9b-hydroxy-4-(2-methylpropyl)-3,5-dioxo-2-propan-2-yl-3a,4,7,8,9,9a-hexahydrofuro[3,2-g]indolizin-2-yl]-7-methyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O.CS(O)(=O)=O.C1=CC([C@H]2C[C@H](CN(C)[C@@H]2C2)C(=O)N[C@]3(C(=O)C4[C@H](C(N5CCC[C@H]5[C@]4(O)O3)=O)C(C)C)C(C)C)=C3C2=CNC3=C1.C1=CC([C@H]2CC(CN(C)[C@@H]2C2)C(=O)N[C@@]3(C(=O)C4[C@@H](C(N5CCCC5[C@@]4(O)O3)=O)CC(C)C)C(C)C)=C3C2=CNC3=C1.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@](C(C21)=O)(NC(=O)[C@H]1CN(C)[C@H]2[C@@H](C=3C=CC=C4NC=C(C=34)C2)C1)C(C)C)C1=CC=CC=C1 QHZUABXEBRGBLP-LKWYKXIFSA-N 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000003906 humectant Substances 0.000 claims 1
- 235000013772 propylene glycol Nutrition 0.000 claims 1
- 229920002554 vinyl polymer Polymers 0.000 claims 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract description 10
- 229940125682 antidementia agent Drugs 0.000 abstract description 5
- 238000004519 manufacturing process Methods 0.000 abstract description 4
- 238000002636 symptomatic treatment Methods 0.000 abstract description 4
- 229940127557 pharmaceutical product Drugs 0.000 abstract 3
- 235000012431 wafers Nutrition 0.000 description 22
- 239000003826 tablet Substances 0.000 description 9
- 238000002560 therapeutic procedure Methods 0.000 description 9
- 238000010521 absorption reaction Methods 0.000 description 8
- 230000009471 action Effects 0.000 description 7
- 230000001965 increasing effect Effects 0.000 description 6
- 230000015654 memory Effects 0.000 description 6
- -1 polyoxyethylene Polymers 0.000 description 6
- 230000003111 delayed effect Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 239000002775 capsule Substances 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 102000012440 Acetylcholinesterase Human genes 0.000 description 3
- 108010022752 Acetylcholinesterase Proteins 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 3
- OIPILFWXSMYKGL-UHFFFAOYSA-N acetylcholine Chemical compound CC(=O)OCC[N+](C)(C)C OIPILFWXSMYKGL-UHFFFAOYSA-N 0.000 description 3
- 229960004373 acetylcholine Drugs 0.000 description 3
- 229940022698 acetylcholinesterase Drugs 0.000 description 3
- 235000014113 dietary fatty acids Nutrition 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 239000000194 fatty acid Substances 0.000 description 3
- 229930195729 fatty acid Natural products 0.000 description 3
- 230000037406 food intake Effects 0.000 description 3
- 229930195712 glutamate Natural products 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 210000002200 mouth mucosa Anatomy 0.000 description 3
- 210000004877 mucosa Anatomy 0.000 description 3
- 210000004400 mucous membrane Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 230000009747 swallowing Effects 0.000 description 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 230000003139 buffering effect Effects 0.000 description 2
- 238000002648 combination therapy Methods 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 150000002191 fatty alcohols Chemical class 0.000 description 2
- 238000010579 first pass effect Methods 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 230000001771 impaired effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 230000003340 mental effect Effects 0.000 description 2
- 238000012544 monitoring process Methods 0.000 description 2
- 230000003232 mucoadhesive effect Effects 0.000 description 2
- 239000002858 neurotransmitter agent Substances 0.000 description 2
- 239000006186 oral dosage form Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- HRANPRDGABOKNQ-ORGXEYTDSA-N (1r,3r,3as,3br,7ar,8as,8bs,8cs,10as)-1-acetyl-5-chloro-3-hydroxy-8b,10a-dimethyl-7-oxo-1,2,3,3a,3b,7,7a,8,8a,8b,8c,9,10,10a-tetradecahydrocyclopenta[a]cyclopropa[g]phenanthren-1-yl acetate Chemical compound C1=C(Cl)C2=CC(=O)[C@@H]3C[C@@H]3[C@]2(C)[C@@H]2[C@@H]1[C@@H]1[C@H](O)C[C@@](C(C)=O)(OC(=O)C)[C@@]1(C)CC2 HRANPRDGABOKNQ-ORGXEYTDSA-N 0.000 description 1
- XZIIFPSPUDAGJM-UHFFFAOYSA-N 6-chloro-2-n,2-n-diethylpyrimidine-2,4-diamine Chemical compound CCN(CC)C1=NC(N)=CC(Cl)=N1 XZIIFPSPUDAGJM-UHFFFAOYSA-N 0.000 description 1
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 208000000044 Amnesia Diseases 0.000 description 1
- 208000019505 Deglutition disease Diseases 0.000 description 1
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 1
- 208000026139 Memory disease Diseases 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 102000004868 N-Methyl-D-Aspartate Receptors Human genes 0.000 description 1
- 108090001041 N-Methyl-D-Aspartate Receptors Proteins 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 229940005524 anti-dementia drug Drugs 0.000 description 1
- 230000002205 anti-dementic effect Effects 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 230000006399 behavior Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000007936 buccal or sublingual tablet Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 210000003169 central nervous system Anatomy 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003412 degenerative effect Effects 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- ADYPXRFPBQGGAH-WVVAGBSPSA-N dihydroergotoxine Chemical compound CS(O)(=O)=O.C([C@H]1C(=O)N2CCC[C@H]2[C@]2(O)O[C@@](C(N21)=O)(C)NC(=O)[C@H]1CN([C@H]2C(C=3C=CC=C4NC=C(C=34)C2)C1)C)C1=CC=CC=C1 ADYPXRFPBQGGAH-WVVAGBSPSA-N 0.000 description 1
- 229940120500 dihydroergotoxine Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000003933 intellectual function Effects 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 150000004668 long chain fatty acids Chemical class 0.000 description 1
- 238000013160 medical therapy Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000006984 memory degeneration Effects 0.000 description 1
- 208000023060 memory loss Diseases 0.000 description 1
- 230000007334 memory performance Effects 0.000 description 1
- 230000006996 mental state Effects 0.000 description 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N methanol Natural products OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 231100000017 mucous membrane irritation Toxicity 0.000 description 1
- 208000015122 neurodegenerative disease Diseases 0.000 description 1
- 210000002569 neuron Anatomy 0.000 description 1
- 230000000324 neuroprotective effect Effects 0.000 description 1
- 238000013546 non-drug therapy Methods 0.000 description 1
- 230000000474 nursing effect Effects 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid group Chemical group C(CCCCCCC\C=C/CCCCCCCC)(=O)O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 208000037821 progressive disease Diseases 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 230000008054 signal transmission Effects 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 229940035044 sorbitan monolaurate Drugs 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/27—Esters, e.g. nitroglycerine, selenocyanates of carbamic or thiocarbamic acids, meprobamate, carbachol, neostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4015—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having oxo groups directly attached to the heterocyclic ring, e.g. piracetam, ethosuximide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- the present invention relates to a sheet-like, quickly disintegrating on contact with moisture, pharmaceutical preparation based on hydrophilic polymers for the treatment of dementia, wherein the dosage form contains a drug combination of at least two active ingredients which are suitable for the treatment of dementias (anti-dementia).
- the invention further relates to the use of such an active substance combination for the production of an orally administrable medicament for the treatment of dementia diseases such as Alzheimer's disease, and to a process for the symptomatic treatment of Alzheimer's disease by oral administration of one of the medicament formulations mentioned.
- Alzheimer's is currently the most common form of dementia, with dementia being understood as the loss of intellectual functions such as thinking, remembering, and associating mental contents that go so far that actions and processes of daily life can no longer be carried out independently. In the terminal stage, dementia can also lead to death.
- Alzheimer's disease is defined in the literature as a progressive, degenerative disease of the CNS associated with impaired memory, intelligence, and behavior, with memory loss not only personal memories but also elemental actions such as food intake, spatial orientation , basic vocabulary and the like.
- impaired memory is a disorder of the neurotransmitters glutamate and acetylcholine.
- Alzheimer's Disease As with all dementias, Alzheimer's Disease, or Alzheimer's disease for short (Alzheimer's disease), with its increasing average age, causes an increasing number of patients in need of treatment.
- the treatment should improve, or at least stabilize, and delay the decline in mental capacity.
- a corresponding drug therapy is required.
- advanced dementia the preservation of the everyday competence of the patient and a delay in the need for care or home admission are ultimately the focus of therapy.
- NMDA neuroprotective NMDA
- Antagonists N-methyl-D-aspartic acid
- Memantine prevents the absorption of glutamate at the NMDA receptors, so that the permanent irritation overload is reduced and signals in the conduction can be recognized again.
- the cell death of nerve cells due to permanent overload can be prevented or delayed in this way.
- the patients become mentally active again and everyday life is increasing. Visible improvements can also be detected in patients who are already in need of care.
- AchE inhibitors acetylcholinesterase inhibitors
- AchE Ace- tylcholinesterase inhibitors
- the therapy is further complicated by the fact that often not only a drug is given in the therapy, but often a combination of different drugs is used. Each additional drug increases but the Danger that his intake, in addition to often other required drugs that must take the usually older patients, forgotten and omitted. In addition, as the number of tablets to be taken increases, the reluctance to ingest often increases, thus decreasing patient compliance.
- the object underlying the invention was therefore to provide pharmaceutical preparations with which a combination therapy for the symptomatic treatment of Alzheimer's can be carried out in a simple and safe manner, and which make it possible to avoid or reduce the abovementioned disadvantages.
- the invention was also based on the object of demonstrating methods for the drug combination therapy of dementia dementia.
- Typical administration forms for administering active substances in therapy are tablets or capsules.
- buccal or sublingual tablets which release the active ingredient in the oral cavity, so that it can be absorbed directly through the oral mucosa.
- the disadvantage of these tablets is an often unpleasant mouthfeel and, due to their compact form, only a slow disintegration of the tablet and a resulting slow release of the active ingredients.
- the object of the present invention is achieved in that in a hydrophilic polymer film, which rapidly decomposes after application in the oral cavity, at least two active ingredients are included, which belong to the group of anti-dementia drugs.
- An active substance is preferably an acetylcholine nesterase inhibitor (AchE inhibitor) and the second is an NMDA antagonist (n-methyl-D-aspartic acid antagonist).
- the improved therapeutic success of a drug combination in the treatment of dementias is due to the fact that different drugs act through different mechanisms, thereby complementing or potentiating the positive effects on memory performance.
- the dose of the individual active ingredients can thus possibly be lowered or the effect improved.
- the orally administered dosage form as a wafer from a rapidly disintegrating hydrophilic polymer the intake of the drugs is ensured by the patient, as it disintegrates immediately in the mouth, so that the administration and monitoring of the intake are simplified for the nursing staff.
- the dosage form according to the invention there is already a combination of active substances adapted to the therapy, so that the administration of the medicaments in non-independent patients must be monitored only once.
- the absorption of the active ingredients through the oral mucosa offers over other peroral forms of administration further the advantages that even patients with dysphagia patients who refuse to take tablets, or Patients who have lost swallowing due to their dementia can receive medication orally.
- the active ingredients are not subject to the first-pass effect. Since in this way no active ingredient is metabolized before reaching the site of action, the initial dosage can be kept as low as possible. Furthermore, variations in the active substance concentration due to incomplete or delayed absorption and delayed action as a function of the amount of food ingested are suppressed or minimized. The adjustment of the patient to the required treatment dose can thus be made more reliable and the need, for example, an intake on an empty stomach can be omitted.
- active ingredients with different mechanisms of action may be present in a combination of active ingredients which have a synergistic effect, so that smaller amounts of the active ingredients can be dosed as a result of the different physiological action and treatment of various symptoms of dementia than would be the case with single-component formulations.
- a positive enhancing effect of this type is known for drug combinations of memantine with an AchE inhibitor.
- the wafers may contain up to five, preferably up to three, and more preferably two active ingredients, at least one of which is an AchE inhibitor, an NMDA antagonist or a nootropic agent.
- the dosages can be adapted to the respective needs and forms of treatment. If the mental state of the patient changes, it can easily be adjusted to a dosage form with a modified combination of active substances, generally with a higher active ingredient concentration.
- the wafer is made of a laminate, then during production e.g. only the layer thickness of an active substance-containing layer or the concentration of the active substance are changed.
- drugs with different active ingredient content but the same active ingredient ratio can be easily prepared via different area blanks of the dosage form. Due to their flat shape, the wafers containing the active compound combinations according to the invention are easy to carry, for example in the wallet, and are immediately available on the way, easy to take and rapidly effective, which facilitates regular use in still mobile patients.
- Suitable anti-dementia agents for use in a combination wafer include the AchE inhibitors, NMDA antagonists and nootropics.
- the drug combination consists of at least two drugs selected from the group comprising the AchE inhibitors, NMDA antagonists and the nootropics.
- Suitable AchE inhibitors are rivastigmine, galanthamine, and donezepil as well as pharmaceutically acceptable salts of these active substances.
- Memantine can be used as an NMDA antagonist.
- the group of the nootropic agents used according to the invention includes piracetam and naftidrofuryl.
- the preparation may contain further active ingredients which are among the vasodilators, calcium antagonists and generally circulation-promoting agents.
- the total active ingredient content of the wafer is between 5% to 50%, preferably between 10% to 30%, and more preferably between 15% to 25%, based on the total weight of the wafer.
- the ratio of the active substances with one another is freely variable and depends on the potency of the active substance and the desired effect or the required dosage.
- water-soluble or swellable polymers are suitable which form a hydrophilic, water-soluble and / or swellable polymer film.
- the polymers of the matrix of the dosage form are selected from the group consisting of dextran, polysaccharides, including starch and starch derivatives, cellulose derivatives, such as carboxymethylcellulose, ethyl or propylcellulose, hydroxypropylmethylcellulose, hydroxypropylcellulose, sodium carboxymethylcellulose (eg. B.
- the polymer film may also consist of a po- lyvinyl alcohol-polyethylene glycol graft copolymer.
- the polymer content of a dosage form according to the invention is preferably from 5 to 95% by weight, more preferably from 15 to 75% by weight, based on the dry weight of the dosage form.
- moisturizers may be added to the film, e.g. Glycerol, propylene glycol, sorbitol, mannitol, polyethylene glycol, polyglycerol esters and the like.
- antioxidants may be added to the wafer to stabilize the film and the active agents, e.g. Vitamin C (ascorbic acid), ascorbyl palmitate, vitamin E (tocopherol acetate), hydroxybenzoic acid derivatives.
- active agents e.g. Vitamin C (ascorbic acid), ascorbyl palmitate, vitamin E (tocopherol acetate), hydroxybenzoic acid derivatives.
- acidic and basic ion exchangers can also be used as stabilizers.
- flavourings and flavorings can mask the often poor taste or smell of the active ingredients and / or give the dosage form a pleasant taste, so that the willingness to take the medication by the patient is significantly improved.
- the active ingredient (s) of the Preparation may also be bound to an acidic or basic ion exchanger for taste masking.
- buffering systems serves, on the one hand, to stabilize the film and the active ingredients against external influences and during storage and, on the other hand, to adjust the pH of the dosage form to a physiologically acceptable pH, so that mucous membrane irritations are avoided .
- a buffer system can also improve the solubility of acidic or basic drugs in the matrix.
- the administration forms according to the invention are thin, for example in the form of a wafer.
- the thickness of the dosage form is preferably 0.1 to 5 mm, more preferably 0.5 to 1 mm.
- the lower limit for the thickness of the dosage forms is about 50 ⁇ m.
- the area of the dosage form is between 0.09 cm 2 and 12 cm 2 , preferably between 1 cm 2 and 8 cm 2 , and particularly preferably between 3 cm 2 and 6 cm 2 .
- the wafers of the present invention include a disintegrant or wicking agent, e.g. a bicarbonate-acid mixture or an aerosil, which is activated by contact with liquid and accelerates the disintegration of the wafer after application and thus also the release of active ingredient.
- a disintegrant or wicking agent e.g. a bicarbonate-acid mixture or an aerosil
- the wafer is present as a foam, so that the release of active ingredient is even faster due to the increased surface area.
- the active ingredients or auxiliaries it is also possible for one or more of the active ingredients or auxiliaries to be present in liquid form in the cavities of the foam.
- permeation enhancers e.g. Substances from the groups of fatty alcohols, fatty acids, polyoxyethylene fatty alcohol ethers, polyoxyethylene fatty acid esters, fatty alcohol esters and fatty acid esters, in particular sorbitan monolaurate or esters of long-chain fatty acids with methyl, ethyl or isopropyl alcohol, or esters of fatty alcohols with acetic acid or lactic acid, or also substances such as DMSO ( Dimethylsulfoxide) and oleic diethanolamine.
- the proportion of these substances, if present, is 0.1% by weight to 25% by weight, preferably from 1% by weight to 10% by weight, in each case based on the total weight of the active substance matrix.
- composition of the wafer may contain compounds that retard drug release (e.g., microencapsulation).
- the wafer has mucoadhesive properties, so that it adheres to the mucous membrane until complete dissolution.
- This embodiment additionally facilitates the monitoring of the administration of the medicaments since the wafer adhering to the mucous membrane can not be spit out.
- At least one of the active ingredients is bound to an ion exchanger, see above that the hydrophilic polymer disintegrates rapidly in the oral cavity, but the release of the active ingredient only delayed or at a changed pH, for example in the gastrointestinal tract, takes place.
- active ingredients having different or higher active and absorption mechanisms can be administered in one dosage form, ie at least one of the released active substances is absorbed at the site of application, eg. B. on the oral mucosa, and the other is transported and resorbed at another location.
- the wafer can also be constructed as a laminate with different layers, wherein the active ingredients are contained in discrete layers, which are spatially separated from each other and differ in their construction.
- the active ingredients can be released at different sites of action or else delayed, if the disintegration time of the different layers of the wafer differs.
- the active ingredients may be arranged in layers which disintegrate at different rates so that the entire preparation has a sustained-release effect.
- only one of the outer layers may be mucoadhesive to promote adherence of the dosage form to the mucosa and to facilitate drug absorption through the mucosa through direct contact.
- Dosage form is preferably in the range of 1 s to 5 minutes, more preferably in the range of 5 seconds to 1 minute, and most preferably in the range of 10 seconds to 30 seconds.
- the dosage forms according to the invention are advantageously suitable for the administration of medicaments in the oral cavity or for rectal, vaginal or intranasal administration.
- the present invention is further directed to the use of one of the active ingredient combination according to the invention for the preparation of an oral dosage form for the treatment of dementia diseases, wherein the dosage form is preferably formulated as a wafer.
- the present invention is directed to a method for the therapeutic treatment of a person suffering from dementia, wherein the administration of a previously described active ingredient combination of anti-dementia agents by means of an orally administered dosage form with at least partial transmucosal absorption of at least one active ingredient.
- the present invention is also directed to a process for the preparation of a sheet-like dosage form which comprises the following steps:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Abstract
La présente invention concerne une composition d'agents pharmaceutiques plane, se décomposant rapidement au contact de l'humidité, à base de polymères hydrophiles, pour le traitement des maladies démentielles, la forme galénique contenant une combinaison d'agents actifs d'au moins deux agents actifs, qui sont appropriés pour le traitement des démences (médicaments antidémence). De préférence, les médicaments antidémence sont choisis parmi le groupe constitué d'inhibiteurs d'anticholinestérase (inhibiteurs AChE) et d'antagonistes de NMDA (antagonistes d'acide N-méthyl-D-aspartique). L'invention concerne de plus l'utilisation d'une telle combinaison d'agents actifs pour la préparation d'un agent pharmaceutique administrable oralement pour le traitement des maladies démentielles telles que la maladie d'Alzheimer, ainsi qu'un procédé pour le traitement symptomatique de la maladie d'Alzheimer par administration orale d'une telle composition d'agents pharmaceutiques.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102006027791A DE102006027791A1 (de) | 2006-06-16 | 2006-06-16 | AchE-NMDA-Kombinationswafer |
PCT/EP2007/004951 WO2007144083A2 (fr) | 2006-06-16 | 2007-06-04 | Comprimé plat combiné ache-nmda |
Publications (1)
Publication Number | Publication Date |
---|---|
EP2029100A2 true EP2029100A2 (fr) | 2009-03-04 |
Family
ID=38686681
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP07725819A Withdrawn EP2029100A2 (fr) | 2006-06-16 | 2007-06-04 | Comprimé plat combiné ache-nmda |
Country Status (8)
Country | Link |
---|---|
US (1) | US20090202597A1 (fr) |
EP (1) | EP2029100A2 (fr) |
JP (1) | JP2009539895A (fr) |
CN (1) | CN101460144A (fr) |
BR (1) | BRPI0711503A2 (fr) |
CA (1) | CA2653030A1 (fr) |
DE (1) | DE102006027791A1 (fr) |
WO (1) | WO2007144083A2 (fr) |
Families Citing this family (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101985040A (zh) * | 2010-11-08 | 2011-03-16 | 北京阜康仁生物制药科技有限公司 | 一种新的药用组合物 |
CN103596551B (zh) * | 2011-06-08 | 2017-02-22 | Lts勒曼治疗系统股份公司 | 含有用于掩味的离子交换树脂的食用口服条或糯米纸囊剂型 |
US9687445B2 (en) | 2012-04-12 | 2017-06-27 | Lts Lohmann Therapie-Systeme Ag | Oral film containing opiate enteric-release beads |
CN105806818B (zh) * | 2016-04-01 | 2019-11-22 | 南京医科大学 | 检测血小板nmda受体活性的方法及其应用 |
DE102017127434A1 (de) * | 2017-11-21 | 2019-05-23 | Lts Lohmann Therapie-Systeme Ag | Taschenförmige oral auflösende Filme mit hoher Wirkstoffbeladung |
CN108926549A (zh) * | 2018-09-27 | 2018-12-04 | 安徽安科余良卿药业有限公司 | 卡巴拉汀凝胶贴膏及其制备方法 |
CN109498643A (zh) * | 2018-12-06 | 2019-03-22 | 北京斯利安药业有限公司 | 一种叶酸组合物及其在制备改善老年失智药物中的应用 |
CN111234323A (zh) * | 2020-03-27 | 2020-06-05 | 南京林业大学 | 一种高强度阻燃性半乳甘露聚糖基复合膜的制备方法 |
DE102021100780A1 (de) | 2021-01-15 | 2022-07-21 | Lts Lohmann Therapie-Systeme Ag. | Oraler dünnfilm mit pva-tris-pufferschicht |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IE82916B1 (en) * | 1990-11-02 | 2003-06-11 | Elan Corp Plc | Formulations and their use in the treatment of neurological diseases |
DE19960154A1 (de) * | 1999-12-14 | 2001-07-12 | Lohmann Therapie Syst Lts | Flache Arzneizubereitung zur transmucosalen Verabreichung von Oxycodon oder einem vergleichbaren Wirkstoff in der Mundhöhle, für die Anwendung in der Schmerztherapie und Suchttherapie |
DE10032456A1 (de) * | 2000-07-04 | 2002-01-31 | Lohmann Therapie Syst Lts | Schnell zerfallende Darreichungsform zur Freisetzung von Wirkstoffen im Mundraum oder in Körperhöhlen |
US20060014773A1 (en) * | 2001-04-19 | 2006-01-19 | Mccleary Edward L | Mental agility lozenge, edible strip, food or drink |
DE10207394B4 (de) * | 2002-02-21 | 2007-03-29 | Lts Lohmann Therapie-Systeme Ag | Geschmacksmaskierte oblatenförmige Arzneizubereitung |
DE10226494A1 (de) * | 2002-06-14 | 2004-01-08 | Lts Lohmann Therapie-Systeme Ag | Filmförmige mucoadhäsive Darreichungsformen zur Verabreichung von Cannabis-Wirkstoffen |
DE10338544B4 (de) * | 2003-08-19 | 2017-08-31 | Janssen Pharmaceutica N.V. | Buccale Formulierungen des Galanthamins und deren Anwendungen |
DE10354894A1 (de) * | 2003-11-24 | 2005-07-07 | Hf Arzneimittelforschung Gmbh | Orale Formulierungen des Desoxypeganins und deren Anwendungen |
-
2006
- 2006-06-16 DE DE102006027791A patent/DE102006027791A1/de not_active Withdrawn
-
2007
- 2007-06-04 WO PCT/EP2007/004951 patent/WO2007144083A2/fr active Application Filing
- 2007-06-04 US US12/308,236 patent/US20090202597A1/en not_active Abandoned
- 2007-06-04 BR BRPI0711503-2A patent/BRPI0711503A2/pt not_active IP Right Cessation
- 2007-06-04 CA CA002653030A patent/CA2653030A1/fr not_active Abandoned
- 2007-06-04 EP EP07725819A patent/EP2029100A2/fr not_active Withdrawn
- 2007-06-04 JP JP2009514664A patent/JP2009539895A/ja not_active Withdrawn
- 2007-06-04 CN CNA2007800205090A patent/CN101460144A/zh active Pending
Non-Patent Citations (1)
Title |
---|
See references of WO2007144083A2 * |
Also Published As
Publication number | Publication date |
---|---|
CA2653030A1 (fr) | 2007-12-21 |
WO2007144083A3 (fr) | 2008-04-17 |
DE102006027791A1 (de) | 2007-12-20 |
US20090202597A1 (en) | 2009-08-13 |
WO2007144083A2 (fr) | 2007-12-21 |
JP2009539895A (ja) | 2009-11-19 |
CN101460144A (zh) | 2009-06-17 |
BRPI0711503A2 (pt) | 2011-11-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2007144083A2 (fr) | Comprimé plat combiné ache-nmda | |
EP1067905B1 (fr) | Formulations de spray | |
EP1067904B1 (fr) | Formulations solides et a decomposition rapide contenant de la cetirizine | |
DE102006027794A1 (de) | Antihypertonie-Kombinationswafer | |
EP2029101A2 (fr) | Comprimé plat combiné pour le diabète de type 2 | |
WO2007144080A2 (fr) | Comprimé plat combinée d'antidépresseurs | |
WO2007144085A1 (fr) | Cachet comprenant une association d'opioïde | |
WO2009036906A1 (fr) | Composition avec combinaison de principes actifs constituée d'un laxatif et d'un agent antimoussant, pour le traitement de la constipation | |
CH662734A5 (de) | Antischnarchmittel. | |
EP2029098A2 (fr) | Comprimé plat combiné pour le sevrage tabagique | |
DE102010024866A1 (de) | Formulierung zur Geschmacksmaskierung | |
DE102006027796A1 (de) | Estrogen-Gestagen-Kombinationen | |
DE10338544B4 (de) | Buccale Formulierungen des Galanthamins und deren Anwendungen | |
DE10354894A1 (de) | Orale Formulierungen des Desoxypeganins und deren Anwendungen | |
DE102020112143B4 (de) | Nicotin - Corona | |
EP3299010B1 (fr) | Forme pharmaceutique orale | |
EP3618812A1 (fr) | Comprimé orodispersible, contenant un anti-histaminique h1 | |
WO2019166098A1 (fr) | Forme pharmaceutique orale contenant du cacao sans théobromine | |
DE202016005032U1 (de) | Schnell zerfallende Efeu-Trinktabletten ohne Zerfallsbeschleuniger | |
DE10301930A1 (de) | Verfahren zur medikamentösen therapeutischen oder prophylaktischen Behandlung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20081121 |
|
AK | Designated contracting states |
Kind code of ref document: A2 Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR |
|
AX | Request for extension of the european patent |
Extension state: AL BA HR MK RS |
|
17Q | First examination report despatched |
Effective date: 20090323 |
|
DAX | Request for extension of the european patent (deleted) | ||
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN |
|
18W | Application withdrawn |
Effective date: 20091205 |